Cover Image

Cardiovascular adverse events during treatment with darunavir-based regimens in an Italian observational study

A Antinori,1 S Rusconi,2 N Gianotti,3 T Bini,4 D Mancusi,5 R Termini51HIV/AIDS Department, National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS, Rome, Italy; 2Infectious Diseases Unit, DIBIC Luigi Sacco, University of Milan, Milan, Italy; 3Infectious Diseases, S...

Full description

Saved in:

Bibliographic Details
Main Authors:	Antinori A (Author), Rusconi S (Author), Gianotti N (Author), Bini T (Author), Mancusi D (Author), Termini R (Author)
Format:	Book
Published:	Dove Medical Press, 2019-05-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study
by: Antinori A, et al.
Published: (2016)

Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice
by: Ranzenigo M, et al.
Published: (2022)

Switching from a Non-Protease Inhibitor-Based Regimen to the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice [Corrigendum]
by: Ranzenigo M, et al.
Published: (2022)

Outcome of Darunavir–Cobicistat-Based Regimens in HIV-Infected People Who Have Experienced Virological Failure
by: Alberton F, et al.
Published: (2024)

Impact of adverse events of antiretroviral treatment on regimen change and mortality in Ugandan children
by: Ntambwe Malangu, et al.
Published: (2010)

Profile of darunavir in the treatment of HIV-infected pediatric and adolescent patients
by: Dobroszycki J, et al.
Published: (2011)

Managing treatment-experienced pediatric and adolescent HIV patients: role of darunavir
by: Michael Neely, et al.
Published: (2009)

Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment
by: Vivek P. Chavda, et al.
Published: (2021)

Appropriate clinical use of darunavir 800 mg
by: Michelle A. Moorhouse, et al.
Published: (2018)

Combating HIV resistance – focus on darunavir
by: Cécile L Tremblay
Published: (2008)

Rationale and clinical utility of the darunavir–cobicistat combination in the treatment of HIV/AIDS
by: Putcharoen O, et al.
Published: (2015)

Biomarkers of Adverse Cardiovascular Events in Kidney Disease
by: L. A. Kamyshnikova, et al.
Published: (2023)

POSSIBLE ADVERSE EVENTS DURING IBD TREATMENT.
by: Adriana Krasteva, et al.
Published: (2011)

Servicio de dispensación: interacción entre darunavir y quetiapina
by: Damià Barris Blundell, et al.
Published: (2022)

THE ROLE OF DOPING IN EMERGENCE OF ADVERSE CARDIOVASCULAR EVENTS
by: Nina Đukanović, et al.
Published: (2011)

Generic substitution of amlodipine is not associated with increased risk of mortality or adverse cardiovascular events: An observational cohort study
by: Boya Zhao, et al.
Published: (2024)

Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients
by: Restelli U, et al.
Published: (2017)

Adverse events in rheumatoid arthritis patients under antimalarial treatment-Is there cardiovascular compromise?
by: Pedro Santos-Moreno, et al.
Published: (2023)

Budget impact analysis of antiretroviral less drug regimen simplification in HIV-positive patients on the Italian National Health Service
by: Restelli U, et al.
Published: (2014)

Adverse Events Leading to Discontinuation of Phototherapy: An Observational Study
by: Isabel Belinchón, et al.
Published: (2020)

Cardiovascular adverse events associated with oral antineoplastic therapy
by: Jacqueline Mota da Silva, et al.

Changes in metabolic parameters and adverse kidney and cardiovascular events during glomerulonephritis and renal vasculitis treatment in patients with and without diabetes mellitus
by: Cynthia C. Lim, et al.
Published: (2021)

Serious Cardiovascular Adverse Events Reported with Intravenous Sedatives: A Retrospective Analysis of the MedWatch Adverse Event Reporting System
by: Matthew S. Duprey, et al.
Published: (2019)

Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database
by: Hui Zhao, et al.
Published: (2023)

Adverse Events during Prone Positioning of Patients with COVID-19 during a Surge in Hospitalizations-Results of an Observational Study
by: Nataša Radovanović, et al.
Published: (2024)

Desenvolvimento de métodos analíticos qualitativos para a análise de darunavir comprimidos
by: Ana Carolina Kogawa, et al.
Published: (2013)

Desenvolvimento de métodos analíticos qualitativos para a análise de darunavir comprimidos
by: Ana Carolina Kogawa, et al.
Published: (2013)

Darunavir Nanoformulation Suppresses HIV Pathogenesis in Macrophages and Improves Drug Delivery to the Brain in Mice
by: Lina Zhou, et al.
Published: (2024)

Vorapaxar for Prevention of Major Adverse Cardiovascular and Limb Events in Peripheral Artery Disease
by: Justin T. Morrison MD, et al.
Published: (2022)

Quantifying the intensity of adverse events with ibuprofen and oxycodone: an observational cohort study
by: Samina Ali, et al.
Published: (2022)

Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature.
by: Philip J Budge, et al.
Published: (2018)

Peripheral Artery Disease Screening in the Community and 1-Year Mortality, Cardiovascular Events, and Adverse Limb Events
by: Kim G. Smolderen, PhD, et al.
Published: (2022)

Adverse Events During Invasive EEG Recordings
by: J Gordon Millichap
Published: (2011)

Adherence to and early adverse events of COVID-19 vaccine in a cohort of 600 Italian breastfeeding and pregnant physicians
by: Marco Montalti, et al.
Published: (2022)

Cardiovascular adverse event reporting in psoriasis and psoriatic arthritis biological therapy clinical trials
by: Sreejan Saha, BA, et al.
Published: (2024)

Biomarkers and Predictors of Adverse Cardiovascular Events in Different Stages of Chronic Kidney Disease
by: Bojan Stopic, et al.
Published: (2022)

Cardiovascular Adverse Events Associated with Monoclonal Antibody Products in Patients with COVID-19
by: Jingrui Zou, et al.
Published: (2022)

TIMI frame count as a predictor of major adverse cardiovascular events during the first month after primary PCI
by: kamyar Amin, et al.
Published: (2024)

Emergence of psychiatric adverse events during antipsychotic treatment in AP-naïve children and adolescents
by: Marie-Line Menard, et al.
Published: (2022)

Direct injection HILICâMS/MS analysis of darunavir in rat plasma applying supported liquid extraction
by: Bokka Ramesh, et al.
Published: (2015)